Tuesday, April 13, 2021

For Critically Ill Patients with Advanced Medical Illnesses and Poor Prognoses, Overuse of Invasive ICU Treatment May Prolong Suffering

Investigator(s): Dong Chang, MD

LOS ANGELES (April 13, 2021) — The Lundquist Institute (TLI) Investigator Dong W. Chang, MD, and his colleagues’ study on critically ill patients and ICU treatments was published in JAMA Internal Medicine. The study – “Evaluation of Time-Limited Trials Among Critically Ill Patients with Advanced Medical Illnesses and Reduction of Nonbeneficial ICU Treatments” – found that training physicians to communicate with family members of critically ill patients using a structured approach, which promotes shared decision-making, improved the quality of family meetings.

Monday, March 8, 2021

Bill & Melinda Gates Medical Research Institute To Develop Formulation

-Agreement advances evolution of synthetic lung surfactants to treat respiratory distress Syndrome in premature infants in Low- and Middle-Income Countries-

Investigator(s): Frans Walther, MD, PhD, FAAP

LOS ANGELES — The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant formulation to be developed for respiratory distress syndrome (RDS) for premature infants in Low- and Middle-Income countries (LMIC). TLI already maintains patents on this invention in the United States, Canada and Europe.
 

Wednesday, March 3, 2021

The Lundquist Institute researchers discovered a natural compound that exhibits almost ideal male contraceptive effects in pre-clinical studies

Investigator(s): Wei Yan, MD, PhD

LOS ANGELES — In a new paper published by Nature Communications, The Lundquist Institute (TLI) Investigator Wei Yan, MD, PhD, and his research colleagues spell out an innovative strategy that has led to the discovery of a natural compound as a safe, effective and reversible male contraceptive agent in pre-clinical animal models. Despite tremendous efforts over the past decades, the progress in developing non-hormonal male contraceptives has been very limited.  

Wednesday, February 10, 2021

The grant will fund clinical trials to study the efficacy of psilocybin in treating the emotional suffering associated with terminal medical illness

Investigator(s): Charles Grob, MD

LOS ANGELES — The Lundquist Institute has received a $1.75 million grant from the Steven & Alexandra Cohen Foundation to fund a multi-site clinical trial to evaluate the efficacy and safety of the compound psilocybin in individuals with severe psychological distress associated with a terminal medical illness. The grant will also support education and outreach programs related to the use of psilocybin within the field of palliative care.

Wednesday, February 3, 2021

Amgen Golden Ticket Winners to Receive Lab Space, Mentoring and Other Benefits

THOUSAND OAKS, Calif. – Amgen (NASDAQ:AMGN) today announced a three-year, Golden Ticket sponsorship of the BioLabs LA at The Lundquist Institute (TLI) life sciences co-working space to accelerate the development of new therapies, medical devices, and diagnostics to advance and improve human health. The BioLabs at TLI shared laboratory space was created to help high-potential life science and biotech startups overcome key obstacles for many early stage organizations, including: access to laboratory infrastructure, programming, and business development mentorship.

Tuesday, January 19, 2021

Ashraf S. Ibrahim, PhD, Lead Author, on publication in the world’s No. 1 Scientific Journal for Microbiology

Investigator(s): Ashraf Ibrahim, PhD

LOS ANGELES — Today Nature Microbiology publishes The Lundquist Institute Investigator Dr. Ashraf Ibrahim and his co-authors’ paper, “Mucoricin is a ricin-like toxin that is critical for the pathogenesis of mucormycosis.”

Tuesday, December 15, 2020

In a Year Dominated by the Global COVID Pandemic, The Institute Kept Moving Forward

 

LOS ANGELES — The Lundquist Institute, a world leader in biomedical research, today released its 2020 Year in Review video. 2020 was an unparalleled year and given the challenge of working against the backdrop of the global COVID pandemic, the Institute had one of its most outstanding years ever.

Thursday, November 19, 2020

California Institute for Regenerative Medicine (CIRM) Funds New Research on Nanotechnology for Stem Cell Implantation and Diabetes Treatment

LOS ANGELES — Two junior Investigators at the The Lundquist Institute, Dr. Eiji Yoshihara and Dr. Lina R. Nih, have received a Quest Award from the California Institute for Regenerative Medicine (CIRM). The Quest Award is for discovery research and aims to promote promising new technologies that could be translated for broad use and improved patient care.

Wednesday, November 18, 2020

First phase of plan includes up to 250,000 square feet of lab, manufacturing and office space

LOS ANGELES – The Lundquist Institute received unanimous approval from the Los Angeles County Board of Supervisors to begin development of a 15-acre biotech park, which will serve as a hub and catalyst for the region’s rapidly-developing bioscience industry.

Tuesday, October 13, 2020

Dr. Richard Casaburi is a world-renowned expert on COPD

Investigator(s): Richard Casaburi, PhD, MD

LOS ANGELES – The Lundquist Institute investigator, Richard Casaburi, PhD, MD, has been presented with the European Respiratory Society’s (ERS) most prestigious honor, the Presidential Award, in recognition of his outstanding work to strengthen respiratory science and medicine worldwide. The award was presented during the ERS annual International Congress 2020 that welcomed more than 33,000 virtual attendees from around the world.